New subgroup analyses presented at Digestive Disease Week® (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase…
Parsippany, NJ – May 11, 2022 – Ferring Pharmaceuticals today announced they will present data from analyses of RBX2660, an…
Primary objective was to compare treatment success of RBX2660 to historical control group A key secondary outcome was the safety…
Ferring Pharmaceuticals has finalized a two-year investment agreement including an acquisition option with Robyn. Together, Ferring and Robyn will provide…
Ferring’s Microbiome Health Index™ is a promising tool that measures disrupted gut microbiota after antibiotic treatment, subsequent gut microbiota restoration,…
In conjunction with C. Diff Infection Awareness Month, Ferring Pharmaceuticals launches new educational website Parsippany, New Jersey – November 11,…
New retrospective analysis found RBX2660 demonstrated efficacy and safety outcomes among a real-world population of C. difficile (CDI) patients, including…
Parsippany, NJ – October 18, 2021 – Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced they will present data from…
Ferring will present four abstracts at the congress including two oral and two poster presentations Ferring is demonstrating its leadership…
Data from award-winning presentation at IDWeek 2021 represents the first time Ferring is showcasing the RBX2660 clinical development program as…